The GLP-1 CVD outcome trials a) Elixa (Lexisenatide) b) Leader (Liraglutide) c) Sustain-6 (Semaglutide) d) Exscel (Weekly Exenatide) e) Harmony (Albiglutide) f) Rewind (Dulaglutide) g) Pioneer 6 (Oral Semaglutide) Elixa Study (Evaluation of Lixisenatide) In ELIXA, the investigational GLP-1 receptor agonist, lixisenatide, neither reduced nor increased cardiovascular events compared with placebo
HPLC purity assay Mass-spec identity Measured content 9.98 mg Test date 08/07/2026 Method HPLC LC-MS Certificate of Analysis available Download or independently verify the full third-party report for this peptide
Comparing Semaglutides Half-Life to Other Medications Putting semaglutides seven-day half-life in context helps appreciate its significance
This improves portion control and satisfaction
Wegovy mimics one gut hormone, GLP-1
Within the pancreas, GIP and GLP-1 together promote cell proliferation and inhibit apoptosis, thereby expanding pancreatic cell mass, while GIP enhances postprandial glucagon response and GLP-1 suppresses it